Age at onset of schizophrenia and neuroleptic dosage

Social Psychiatry and Psychiatric Epidemiology

Volumn 34, Issue 12, 1999, Pages 622-626

  Dernovsek, M Z ^a   Tavcar, R ^a  

^a UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE DECANOATE; NEUROLEPTIC AGENT; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CONSULTATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTPATIENT; PROGNOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEX DIFFERENCE;

EID: 0033399699     PISSN: 09337954     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001270050184     Document Type: Article

References (55)

1. Lewine RRJ (1988) Gender and schizophrenia. In: Tsuang MT, Sompson JC (eds) Handbook of schizophrenia, vol. 3. Nosology, epidemiology and genetics. Elsevier Science Publishers, Amsterdam, pp 379-397
2. Riecher A, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Munk-Jørgensen P, Stromgren E, Häfner H (1991) Gender differences in age at onset and course of schizophrenic disorders. In: Häfner H, Gattaz WF (eds) Search for the causes of schizophrenia, Springer-Berlin, pp 14-33
3. Beiser M, Erickson D, Fleming J, Iacono W (1993) Establishing the onset of psychotic illness. Am J Psychiatry 150: 1349-1354
4. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, an der Heiden W (1992) IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res 6: 209-223
5. Häfner H, Maurer K, Löffler W, Riecher-Rössler A (1993) The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162: 80-86
6. Angermeyer MC, Kühn L (1988) Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci 237: 351-364
7. Kirch DG, Keith SJ, Matthews SM (1992) Research on first-episode psychosis: report on a National Institute of Mental Health Workshop. Schizophr Bull 18: 179-184
8. Corrigan PW, Gleason W, Cohler BJ, Luchins D, Addis I (1995) Are there patients with late-onset schizophrenia in state hospitals? Schizophr Res 15: 261-264
9. Bloom FE (1993) Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 50: 224-227
10. De Lisi LE (1992) The significance of age at onset for schizophrenia. Schizophr Bull 18: 209-215
11. O'Callaghan E, Gibson T, Colohan HA, Buckley P, Walshe DG, Larkin C, Waddington JL (1992) Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study. BMJ 305: 1256-1259
12. Galdos PM, van Os JJ, Murray RM (1993) Puberty and the onset of psychosis. Schizophr Res 10: 7-14
13. Häfner H, an der Heiden W, Hambrecht M, Riecher-Rössler A, Maurer K, Löffler W, Fätkenheuer B (1993) Ein Kapitel systematischer Schizophrenieforschung - die Suche nach kausalen Erklärungen für die Geschlechtsunterschied im Ersterkrankungsalter. Nervenarzt 64: 706-716
14. Riecher-Rössler A, Löffler W, Munk-Jørgensen P (1997) What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247: 195-208
15. Krausz M, Müller-Thomsen T (1993) Schizophrenia with onset in adolescence; an 11-year followup. Schizophr Bull 19: 831-841
16. Eaton WW, Mortensen PB, Herrman H, Freeman H, Bilker W, Burgess P, Wooff K (1992) Long-term course of hospitalization for schizophrenia. I. Risk for rehospitalization. Schizophr Bull 18: 217-228
17. Hubschmid T, Ciompi L (1990) Prädiktoren des Schizophrenieverlaufs - eine Literaturübersicht. Fortschr Neurol Psychiatr 58: 359-366
18. Crow TJ (1995) Brain changes and negative symptoms in schizophrenia. Psychopathology 28: 18-21
19. Häfner H, Nowotny B (1995) Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 245: 80-92
20. Sandyk R, Kay SR (1991) Drug-induced Parkinsonism: relationship to age at onset of schizophrenia. Funct Neurol 6: 151-157
21. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA (1997) Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 154: 475-482
22. Wei J, Xu H, Ramchand CN, Hemmings GP (1995) Low concentrations of serum tyrosine in neuroleptic-free schizophrenics with an early onset. Schizophr Res 14: 257-260
23. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, Rabin BS (1995) Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 52: 668-672
24. Aso M, Kurachi M, Suzuki M, Yuasa S, Matsi M, Saitoh O (1995) Asymmetry of the ventricle and age at the onset of schizophrenia. Eur Arch Psychiatry Clin Neurosci 245: 142-144
25. Morris AG, Gaitonde E, McKenna PJ, Mollon JD, Hunt DM (1995) CAG repeat expansions and schizophrenia: association with disease in females and with early age-at-onset. Hum Mol Genet 4: 1957-1961
26. Jeste DV, McAdams LA, Palmer BW, Braff D, Jernigan TL, Paulsen JS, Stout JC, Symonds LL, Bailey A, Heaton RK (1998) Relationship of neuropsychological and MRI measures to age of onset of schizophrenia. Acta Psychiatr Scand 98: 156-164
27. Krawiecka M, Goldberg D, Vaughan M (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 55: 299-308
28. Davis JM (1974) Dose equivalence of the antipsychotic drugs. J Psychiatry Res 11: 65-69
29. Brotman AW, McCormic S (1989) Converting doses of fluphenazine decanoate to oral equivalents. Am J Psychiatry 146: 815-816
30. Kulhanek F (1995) Über die Bedeutung neuroleptischer Äquivalenzdosen. In: Hinterhuber H, Fleischhacker WW, Meise U (eds) Die Behandlung der Schizophrenien State of the art. VIP Integrative Psychiatrie, Innsbruck, pp 229-239
31. Matthews DE, Farewell VT (1990) Using and understanding medical statistics. Karger, Basel
32. Bland M (1995) An introduction to medical statistics. Oxford University Press, Oxford
33. Salokangas RK (1993) First-contact rate for schizophrenia in community psychiatric care. Consideration of the oestrogen hypothesis. Eur Arch Psychiatry Clin Neurosci 242: 337-346
34. Folnegovic Z, Folnegovic-Smalc V (1994) Schizophrenia in Croatia: age at onset differences between males and females. Schizophr Res 14: 83-91
35. Maurer K, Häfner H (1995) Methodological aspects of onset assessment in schizophrenia. Schizophr Res 15: 265-276
36. Kane J (1989) The current status of neuroleptic therapy. J Clin Psychiatry 50: 322-328
37. Zvan V (1989) Principles of the neuroleptic maintenance therapy for psychoses (in Slovenian). Zdravstveno Varstvo 28: 335-341
38. Fleischhacker WW (1995) Die pharmakologische Behandlung schizophrener Störungen. In: Hinterhuber H, Fleischhacker WW, Meise U (eds) Die Behandlung der Schizophrenien State of the art. VIP Integrative Psychiatrie, Innsbruck, pp 93-115
39. American Psychiatric Association (1997) Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154 [Suppl]: 1-63
40. Rosenbluth R, Tang S (1987) Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with Occidentals? Can J Psychiatry 32: 270-274
41. Lin KM, Matsuda A, Nuccio I (1996) Neuroleptic dosage in psychiatric outpatients. Psychiatr Serv 47: 536
42. Vinarova E, Vinar O, Kalvach Z (1984) Smokers need higher doses of neuroleptic drugs. Biol Psychiatry 19: 1265-1268
43. Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194
44. Levin ED, Wilson W, Rose JE, McEvoy J (1996) Nicotinehaloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15: 429-436
45. Salokangas RK (1995) Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr Res 16: 7-16
46. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J, Woerner M, Cooper T (1995) Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 152: 698-703
47. Cannon M, Byrne M, Cotter D, Sham P, Larkin C, O'Callaghan E (1994) Further evidence for anomalies in the handprints of patients with schizophrenia: a study of secondary creases. Schizophr Res 13: 179-184
48. Kane JM, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group (1988) Clozapine for the treatment resistant schizophrenia: a double blind comparison study with chlorpromazine. Arch Gen Psychiatry 45: 789-796
49. Drew LR, Minehan K, Cowley J (1996) Clozapine and excessive psychotropic drug use. Psychiatr Serv 47: 876
50. Avnon M, Kunin A (1995) Risperidone response after no clozapine response. Br J Psychiatry 167: 699
51. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166: 712-726
52. Tollefson GD (1994) Olanzapine: novel antipsychotic with a broad spectrum profile. Neuropsychopharmacology 10: 805
53. Barnas C, Stuppäck C, Miller CH, Haring C, Sperner-Unterweger B, Fleischhacker WW (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 7: 23-27
54. Dunn CJ, Fitton A (1996) Sertindole: new drug profile. CNS Drugs 5: 224-230
55. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15 [Suppl 1]: 24-29